146 related articles for article (PubMed ID: 9589671)
1. Growth hormone status during long-term hexarelin therapy.
Rahim A; O'Neill PA; Shalet SM
J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671
[TBL] [Abstract][Full Text] [Related]
2. Does desensitization to hexarelin occur?
Rahim A; Shalet SM
Growth Horm IGF Res; 1998 Apr; 8 Suppl B():141-3. PubMed ID: 10990150
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
Mauras N; Doi SQ; Shapiro JR
J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
6. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
[TBL] [Abstract][Full Text] [Related]
7. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
[TBL] [Abstract][Full Text] [Related]
9. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.
Rahim A; O'Neill PA; Shalet SM
Clin Endocrinol (Oxf); 1999 Jan; 50(1):77-84. PubMed ID: 10341859
[TBL] [Abstract][Full Text] [Related]
10. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
[TBL] [Abstract][Full Text] [Related]
11. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
12. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
[TBL] [Abstract][Full Text] [Related]
14. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
[TBL] [Abstract][Full Text] [Related]
15. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency.
Gill MS; Toogood AA; O'Neill PA; Thorner MO; Shalet SM; Clayton PE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2562-5. PubMed ID: 9661643
[TBL] [Abstract][Full Text] [Related]
16. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
18. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
